Inappropriate antibiotic use in the COVID-19 era: Factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID.
Acute Kidney Injury
/ etiology
Aged
Anti-Bacterial Agents
/ administration & dosage
C-Reactive Protein
/ analysis
COVID-19
/ complications
Comorbidity
Cough
/ etiology
Dyspnea
/ etiology
Female
Fever
/ etiology
Humans
Inappropriate Prescribing
/ adverse effects
Logistic Models
Male
Middle Aged
Odds Ratio
Registries
Retrospective Studies
Risk Factors
SARS-CoV-2
/ isolation & purification
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
03
2021
accepted:
25
04
2021
entrez:
11
5
2021
pubmed:
12
5
2021
medline:
25
5
2021
Statut:
epublish
Résumé
Most patients with COVID-19 receive antibiotics despite the fact that bacterial co-infections are rare. This can lead to increased complications, including antibacterial resistance. We aim to analyze risk factors for inappropriate antibiotic prescription in these patients and describe possible complications arising from their use. The SEMI-COVID-19 Registry is a multicenter, retrospective patient cohort. Patients with antibiotic were divided into two groups according to appropriate or inappropriate prescription, depending on whether the patient fulfill any criteria for its use. Comparison was made by means of multilevel logistic regression analysis. Possible complications of antibiotic use were also identified. Out of 13,932 patients, 3047 (21.6%) were prescribed no antibiotics, 6116 (43.9%) were appropriately prescribed antibiotics, and 4769 (34.2%) were inappropriately prescribed antibiotics. The following were independent factors of inappropriate prescription: February-March 2020 admission (OR 1.54, 95%CI 1.18-2.00), age (OR 0.98, 95%CI 0.97-0.99), absence of comorbidity (OR 1.43, 95%CI 1.05-1.94), dry cough (OR 2.51, 95%CI 1.94-3.26), fever (OR 1.33, 95%CI 1.13-1.56), dyspnea (OR 1.31, 95%CI 1.04-1.69), flu-like symptoms (OR 2.70, 95%CI 1.75-4.17), and elevated C-reactive protein levels (OR 1.01 for each mg/L increase, 95% CI 1.00-1.01). Adverse drug reactions were more frequent in patients who received ANTIBIOTIC (4.9% vs 2.7%, p < .001). The inappropriate use of antibiotics was very frequent in COVID-19 patients and entailed an increased risk of adverse reactions. It is crucial to define criteria for their use in these patients. Knowledge of the factors associated with inappropriate prescribing can be helpful.
Sections du résumé
BACKGROUND
Most patients with COVID-19 receive antibiotics despite the fact that bacterial co-infections are rare. This can lead to increased complications, including antibacterial resistance. We aim to analyze risk factors for inappropriate antibiotic prescription in these patients and describe possible complications arising from their use.
METHODS
The SEMI-COVID-19 Registry is a multicenter, retrospective patient cohort. Patients with antibiotic were divided into two groups according to appropriate or inappropriate prescription, depending on whether the patient fulfill any criteria for its use. Comparison was made by means of multilevel logistic regression analysis. Possible complications of antibiotic use were also identified.
RESULTS
Out of 13,932 patients, 3047 (21.6%) were prescribed no antibiotics, 6116 (43.9%) were appropriately prescribed antibiotics, and 4769 (34.2%) were inappropriately prescribed antibiotics. The following were independent factors of inappropriate prescription: February-March 2020 admission (OR 1.54, 95%CI 1.18-2.00), age (OR 0.98, 95%CI 0.97-0.99), absence of comorbidity (OR 1.43, 95%CI 1.05-1.94), dry cough (OR 2.51, 95%CI 1.94-3.26), fever (OR 1.33, 95%CI 1.13-1.56), dyspnea (OR 1.31, 95%CI 1.04-1.69), flu-like symptoms (OR 2.70, 95%CI 1.75-4.17), and elevated C-reactive protein levels (OR 1.01 for each mg/L increase, 95% CI 1.00-1.01). Adverse drug reactions were more frequent in patients who received ANTIBIOTIC (4.9% vs 2.7%, p < .001).
CONCLUSION
The inappropriate use of antibiotics was very frequent in COVID-19 patients and entailed an increased risk of adverse reactions. It is crucial to define criteria for their use in these patients. Knowledge of the factors associated with inappropriate prescribing can be helpful.
Identifiants
pubmed: 33974637
doi: 10.1371/journal.pone.0251340
pii: PONE-D-21-09419
pmc: PMC8112666
doi:
Substances chimiques
Anti-Bacterial Agents
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0251340Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Clin Infect Dis. 2021 May 18;72(10):e533-e541
pubmed: 32820807
Anaerobe. 2020 Aug;64:102233
pubmed: 32593567
Risk Manag Healthc Policy. 2020 Nov 13;13:2593-2599
pubmed: 33223859
Rev Clin Esp. 2020 Nov;220(8):480-494
pubmed: 33994573
Travel Med Infect Dis. 2020 Mar - Apr;34:101663
pubmed: 32289548
Med Sci Monit. 2021 Jan 03;27:e929783
pubmed: 33388738
Clin Microbiol Infect. 2020 Jul;26(7):808-810
pubmed: 32360446
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
J Hosp Infect. 2020 Aug;105(4):593-595
pubmed: 32590012
Ann Intern Med. 2020 Aug 18;173(4):304-305
pubmed: 32379883
Infect Control Hosp Epidemiol. 2021 Mar;42(3):378-379
pubmed: 32408916
Infect Control Hosp Epidemiol. 2020 Jun;41(6):744-745
pubmed: 32167442
Clin Infect Dis. 2021 Mar 1;72(5):905-906
pubmed: 32544219
Nat Rev Microbiol. 2020 Aug;18(8):409-410
pubmed: 32488173
J Hosp Infect. 2021 Jan;107:114-115
pubmed: 33217492
Clin Microbiol Infect. 2021 Apr;27(4):520-531
pubmed: 33418017
Clin Med (Lond). 2021 Jan;21(1):e71-e76
pubmed: 33355197
Clin Infect Dis. 2020 Dec 17;71(10):2736-2743
pubmed: 32361747
Expert Rev Anti Infect Ther. 2021 Feb;19(2):147-163
pubmed: 32853038
J Antimicrob Chemother. 2020 Jul 1;75(7):1681-1684
pubmed: 32433765
J Infect. 2020 Aug;81(2):e148-e149
pubmed: 32512022
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Sci Total Environ. 2020 Nov 25;745:141053
pubmed: 32702547
J Allergy Clin Immunol Pract. 2019 Sep - Oct;7(7):2105-2114
pubmed: 31495420
Emerg Infect Dis. 2020 Sep;26(9):
pubmed: 32441243
J Antimicrob Chemother. 2020 Nov 1;75(11):3386-3390
pubmed: 32766706
Clin Microbiol Infect. 2021 Jan;27(1):61-66
pubmed: 33010444
Infez Med. 2020 Jun 1;28(suppl 1):29-36
pubmed: 32532935
Clin Microbiol Infect. 2021 Jan;27(1):83-88
pubmed: 32745596
Curr Opin Crit Care. 2020 Oct;26(5):433-441
pubmed: 32739970
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
J Glob Antimicrob Resist. 2020 Dec;23:167-173
pubmed: 32971291
J Med Virol. 2021 Mar;93(3):1489-1495
pubmed: 32808695
Lung Cancer. 2020 Aug;146:19-22
pubmed: 32505076